

Supporting information

Pd-Catalyzed Regio- and Enantioselective Allylic Substitution with 2-Pyridones

Sardaraz Khan, Babar Hussain Shah, Ijaz Khan, Meiqi Li, Yong Jian Zhang*

School of Chemistry and Chemical Engineering, and Shanghai Key Laboratory of Electrical Insulation
and Thermal Aging, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China

E-mail: yjian@sjtu.edu.cn

Table of Contents

General experimental details.....	S2
General procedure for the synthesis of allylic carbonates (1b-1d)	S3
General procedure for the synthesis of allylic carbonates (1g-1i).....	S3
General procedure for the synthesis of compound 7	S3
Table S1. Solvent Screening for the Pd-catalyzed allylic substitution of 1b with 2-pyridones 2	S4
General procedure for the Pd-catalyzed allylic substitution of 1b with various substituted 2-pyridones 2	S4-S5
General procedure for ring-closing metathesis of 3a and 4a to 9a and 9b	S11
References.....	S13
NMR charts.....	S14-S40
HPLC charts.....	S41-S59

General experimental details


Analytical thin-layer chromatography (TLC) was carried out using 0.2-mm commercial silica gel plates (Yantai Jiangyou Silica Gel Development Co., Ltd., silica gel HSGF 254). Preparative column chromatography employing silica gel (Qingdao Shenghai Fine Silica Gel Chemical Co., Ltd., 200-300 mesh) was performed according to the method of Still. High-resolution mass spectra (HRMS) were performed at Instrumental Analysis Center of Shanghai Jiao Tong University using ESI method. Proton nuclear magnetic resonance (^1H NMR) spectra were recorded with a Bruker AVANCE III HD 500 (500 MHz) spectrometer. Chemical shifts are reported in delta (δ) units, parts per million (ppm) downfield from trimethylsilane or deuterated water and ppm relative to the center of the singlet at 7.26 ppm for deuteriochloroform, or ppm relative to the center of the quintet at 3.34 ppm for deuteriomethanol. Coupling constants are reported in Hertz (Hz). Carbon-13 nuclear magnetic resonance (^{13}C NMR) spectra were recorded with a Bruker AVANCE III HD 500 (125 MHz) spectrometer. Chemical shifts are reported in delta (δ) units, ppm relative to the center of the triplet at 77.0 ppm for deuteriochloroform and ppm relative to the center of the septet at 49.54 ppm for deuteriomethanol. ^{13}C NMR spectra were routinely run with broadband decoupling. High performance liquid chromatography (HPLC) was performed with Thermofisher spectrometers using chiral columns. Optical rotations were measured on a SGW[®]-1polarimeter. All of the palladium sources and phosphine ligands were purchased from Sinocompound Co. and used as received.

General procedure for the synthesis of allylic carbonates (1b-1d)


Mono protection of 1,4-butene diol was carried out with di-*tert*-butyl dicarbonate, acetyl chloride and benzoyl chloride according to reported procedures,¹ all characterization data are in accordance with literature.

General procedure for the synthesis of allylic carbonates (1g-1i)

Allylic carbonates **1g-1i** were synthesized according to reported procedure.² To an oven dried 100 mL round bottom flask equipped with a stir bar, was added protected alcohol **B** (1.09 g, 3.78 mmol), but-3-en-1-ol (0.272 g, 3.78 mmol), Hoveyda-Grubbs 2nd generation (3 mol %) and DCM (8.0 mL). The mixture was stirred at 40 °C for 18 hours. Then the solvent was removed in vacuum. The residue was purified by flash column chromatography on silica gel to afford desired product **1g**.




tert-butyl (5-hydroxypent-2-en-1-yl) carbonate




Yield: 84 %; colorless oil; (*E*:*Z* = 5:1); ¹H NMR (500 MHz, CDCl₃) δ 5.83–5.68 (m, 2H), 4.52 (d, *J* = 6.2 Hz, 2H), 3.70–3.65 (m, 2H), 2.36–2.32 (m, 2H), 1.49 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 153.3, 132.4, 126.4, 82.0, 67.2, 61.5, 35.5, 27.7; HRMS (ESI-MS): Calcd. for C₁₀H₁₈O₄ (*M*+*Na*): 225.1103, Found: 225.1094.

tert-butyl (6-hydroxyhex-2-en-1-yl) carbonate



Yield: 79 %; yellow oil; (*E*:*Z* = 1.2:1); ¹H NMR (500 MHz, CDCl₃) for *E* isomer: δ 5.84–5.78 (m, 1H), 5.65–5.59 (m, 1H), 4.50 (d, *J* = 6.5 Hz, 2H), 3.69–3.62 (m, 2H), 2.18–3.13 (m, 2H), 1.69–1.64 (m, 2H), 1.48 (s, 9H); ¹H NMR (500 MHz, CDCl₃) for *Z* isomer: 5.57–5.49 (m, 2H), 4.10–4.06 (m, 2H), 3.69–3.62 (m, 2H), 2.46–2.35 (m, 2H), 2.34–2.25 (m, 2H), 1.48 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) for *E* isomer: δ 153.4, 135.9, 129.2, 81.8, 66.2, 61.6, 35.8, 32.0, 27.6; ¹³C NMR (125 MHz, CDCl₃) for *Z* isomer: 153.2, 128.6, 128.0, 123.9, 67.4, 31.5, 30.9, 28.4, 26.8; HRMS (ESI-MS): Calcd. for C₁₁H₂₀O₄ (*M*+*Na*): 239.1259, Found: 239.1252.

(*Z*)-*tert*-butyl (4-methoxybut-2-en-1-yl) carbonate




Yield: 77 %; colorless oil; ¹H NMR (500 MHz, CDCl₃) δ 5.79–5.70 (m, 2H), 4.65 (d, *J* = 5.8 Hz, 2H), 4.04 (d, *J* = 5.3 Hz, 2H), 3.34 (m, 3H), 1.49 (m, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 153.2, 130.7, 126.3, 82.0, 67.9, 62.4, 58.0, 27.6; HRMS (ESI-MS): Calcd. for C₁₀H₁₈O₄ (*M*+*Na*): 225.1103, Found: 225.1093.

General procedure for the synthesis of compound 7


Substrate **7** was synthesized according to reported procedure.³

(*Z*)-4-(pyridin-2-yloxy)but-2-en-1-ol



Yield: 60 %; yellow oil; ^1H NMR (500 MHz, CDCl_3) δ 8.09 (d, J = 4.6 Hz, 1H), 7.56 (dd, J = 8.2, 7.3 Hz, 1H), 6.86 (dd, J = 7.1, 5.2 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 5.89–5.84 (m, 1H), 5.78–5.73 (m, 1H), 4.96 (d, J = 6.9 Hz, 2H), 4.31 (d, J = 6.4 Hz, 2H), 4.18 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.1, 146.1, 138.8, 132.4, 126.8, 116.7, 111.5, 61.6, 58.6; HRMS (ESI-MS): Calcd. for $\text{C}_9\text{H}_{11}\text{NO}_2$ ($\text{M}+\text{Na}$): 174.0531, Found: 174.0528.


Table S1. Solvent Screening for the Pd-catalyzed allylic substitution of 1b with 2-pyridones 2



entry	solvent	yield (%) ^b	ee (%) ^c
1	THF	87	95: 5
2	Toluene	90	92.5:7.5
3	CH_2Cl_2	92	80.5:19.5
4	Et_2O	58	84:16
5	MTBE	41	82.5:17.5
6	CH_3CN	30	75:25
7 ^d	MeOH	59	80.5:19.5

^a Reaction conditions: $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (2.5 mol %), ligand (10 mol %), **1** (0.2 mmol), **2a** (0.2 mmol), solvent (2.0 mL), 36 h. ^b Isolated yields. ^c Determined by HPLC using a chiral stationary phase. The absolute configuration was assigned by comparing the sign of the optical rotation with that reported.^{3a} ^d The ratio of branch to linear selectivity for entry 7 is 3.7:1.


General procedure for the Pd-catalyzed allylic substitution of 1b with various substituted 2-pyridones 2



To an oven dry 10 mL Schlenck flask equipped with a stir bar, was added $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (5.2 mg,


2.5 mol %), phosphoramidite ligand **L2** (10.8 mg, 10 mol %), allylic carbonate **1b** (37.6 mg, 0.2 mmol) and 2-hydroxypyridine (19.0 mg, 0.2 mmol). The reaction tube was sealed with rubber-septum, then evacuated and backfilled with nitrogen (this process was repeated a total of three times) and anhydrous THF (2 mL) was added sequentially via syringe. The mixture was stirred at -40 °C for 36 hours. Then the solvent was removed in vacuum. The residue was purified by flash column chromatography on silica gel to afford product **3a**.

(S)-1-(1-hydroxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 87%; white solid; 88-90 °C; $[\alpha]_D^{25} = -23.80$ ($c = 0.28$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.40 (dd, $J = 6.9, 2.0$ Hz, 1H), 7.36–7.31 (m, 1H), 6.56 (dd, $J = 9.8, 8.3$ Hz, 1H), 6.24 (dd, $J = 6.8, 6.8$ Hz, 1H), 6.00 (ddd, $J = 17.2, 10.6, 5.4$ Hz, 1H), 5.61–5.55 (m, 1H), 5.39 (d, $J = 10.8$ Hz, 1H), 5.28 (d, $J = 17.4$ Hz, 1H), 4.10 (bs, 1H), 4.01 (dd, $J = 11.8, 4.4$ Hz, 1H), 3.92 (dd, $J = 11.6, 6.7$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.2, 139.5, 135.6, 133.1, 120.4, 119.5, 106.5, 63.2, 59.3; HRMS (ESI-MS): Calcd. for $\text{C}_9\text{H}_{11}\text{NO}_2$ ($\text{M}+\text{H}$): 166.0868, Found: 166.0868; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 2/8, $t_{\text{major}} = 12.99$ min, $t_{\text{minor}} = 16.71$ min; 95:5 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-3-methylpyridin-2(1H)-one



Yield: 91%; yellow oil; $[\alpha]_D^{25} = -38.54$ ($c = 1.16$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.25 (d, $J = 6.9$ Hz, 1H), 7.21 (d, $J = 6.1$ Hz, 1H), 6.17 (dd, $J = 6.8, 6.8$ Hz, 1H), 6.01 (ddd, $J = 17.4, 10.7, 5.6$ Hz, 1H), 5.66–5.58 (m, 1H), 5.38 (d, $J = 10.6$ Hz, 1H), 5.28 (d, $J = 17.4$ Hz, 1H), 4.02 (dd, $J = 11.1, 5.0$ Hz, 1H), 3.94–3.90 (m, 2H), 2.13 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.5, 136.9, 133.3, 132.8, 129.5, 119.3, 106.2, 63.7, 59.8, 17.4; HRMS (ESI-MS): Calcd. for $\text{C}_{10}\text{H}_{13}\text{NO}_2$ ($\text{M}+\text{H}$): 180.1025, Found: 180.1026; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 3/7, $t_{\text{major}} = 9.71$ min, $t_{\text{minor}} = 11.89$ min; 92:8 *er*.


(S)-1-(1-hydroxybut-3-en-2-yl)-4-methylpyridin-2(1H)-one



Yield: 83%; yellow oil; $[\alpha]_D^{25} = -13.90$ ($c = 1.00$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.25 (dd, $J = 7.1, 2.4$ Hz, 1H), 6.38 (s, 1H), 6.09 (d, $J = 7.2$ Hz, 1H), 5.98 (ddd, $J = 16.4, 10.7, 5.4$ Hz, 1H), 5.54–5.50 (m, 1H), 5.37 (d, $J = 10.8$ Hz, 1H), 5.26 (d, $J = 17.4$ Hz, 1H), 4.00–3.94 (m, 2H), 3.89 (dd, $J = 7.2, 3.4$ Hz, 1H), 2.17 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.3, 151.3, 134.5, 133.2, 119.4, 118.9,


109.2, 63.5, 59.2, 21.1; HRMS (ESI-MS): Calcd. for $C_{10}H_{13}NO_2$ (M+H): 180.1025, Found: 180.1025; HPLC conditions: Chiralcel AD-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/13, $t_{\text{minor}} = 12.74$ min, $t_{\text{major}} = 14.76$ min; 91.5:8.5 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-5-methylpyridin-2(1H)-one




Yield: 86%; yellow oil; $[\alpha]_D^{25} = -14.11$ ($c = 0.60$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.20 (dd, $J = 9.2, 2.5$ Hz, 1H), 7.12 (s, 1H), 6.54 (d, $J = 9.2$ Hz, 1H), 6.00 (ddd, $J = 17.3, 10.7, 5.5$ Hz, 1H), 5.55–5.50 (m, 1H), 5.39 (d, $J = 10.6$ Hz, 1H), 5.29 (d, $J = 17.4$ Hz, 1H), 4.03 (dd, $J = 11.6, 4.0$ Hz, 1H), 3.91 (dd, $J = 11.8, 7.2$ Hz, 1H), 3.66 (bs, 1H), 2.09 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 162.6, 142.1, 133.1, 132.9, 120.2, 119.5, 115.7, 63.7, 59.9, 17.3; HRMS (ESI-MS): Calcd. for $C_{10}H_{13}NO_2$ (M+H): 180.1025, Found: 180.1024; HPLC conditions: Chiralcel AD-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/9, $t_{\text{major}} = 7.33$ min, $t_{\text{minor}} = 9.37$ min; 90:10 *er*.

benzyl (S)-1-(1-hydroxybut-3-en-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate



Yield: 87%; light yellow oil; $[\alpha]_D^{25} = -44.08$ ($c = 1.44$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 8.02 (s, 1H), 7.92 (s, 1H), 7.39–7.30 (m, 5H), 7.02 (dd, $J = 7.0, 1.8$ Hz, 1H), 6.25 (dd, $J = 7.2, 7.2$ Hz, 1H), 5.95 (ddd, $J = 16.3, 10.6, 5.6$ Hz, 1H), 5.56–5.52 (m, 1H), 5.36 (d, $J = 10.8$ Hz, 1H), 5.25 (d, $J = 17.4$ Hz, 1H), 5.18 (s, 2H), 3.97 (dd, $J = 11.4, 4.2$ Hz, 1H), 3.90 (dd, $J = 11.6, 7.2$ Hz, 1H), 3.40 (bs, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 157.4, 153.3, 135.8, 132.6, 129.1, 128.5, 128.2, 128.0, 127.0, 120.2, 119.7, 106.8, 67.0, 63.3, 60.2; HRMS (ESI-MS): Calcd. for $C_{17}H_{18}N_2O_4$ (M+H): 315.1345, Found: 315.1340; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 2/8, $t_{\text{major}} = 10.10$ min, $t_{\text{minor}} = 21.68$ min; 89:11 *er*.


(S)-N-(1-(1-hydroxybut-3-en-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)-5-methylisoxazole-3-carboxamide



Yield: 83%; white solid; 150–152 °C; $[\alpha]_D^{25} = -14.39$ ($c = 0.88$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 9.62 (s, 1H), 8.42 (dd, $J = 7.4, 1.8$ Hz, 1H), 7.18 (dd, $J = 7.0, 1.8$ Hz, 1H), 6.48 (s, 1H), 6.31 (dd, $J = 7.2, 7.2$ Hz, 1H), 6.02 (ddd, $J = 16.6, 10.7, 5.7$ Hz, 1H), 5.60–5.57 (m, 1H), 5.41 (d, $J = 10.7$ Hz, 1H), 5.31 (d, $J = 17.4$ Hz, 1H), 4.09–3.97 (m, 2H), 3.34 (dd, $J = 5.9, 5.8$ Hz, 1H), 2.50 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 171.5, 158.6, 157.6, 132.5, 128.9, 128.3, 123.0, 119.9, 106.6, 101.1, 63.3, 60.6,


30.9, 12.3; HRMS (ESI-MS): Calcd. for $C_{14}H_{15}N_3O_4$ (M+H): 290.1141, Found: 290.1138; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 2/8, t_{minor} = 10.60 min, t_{major} = 12.32 min; 92.5:7.5 *er*.

(S)- 5-fluoro-1-(1-hydroxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 81%; yellow oil; $[\alpha]_D^{25} = -3.67$ ($c = 1.24$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.37 (dd, $J = 4.4, 3.4$ Hz, 1H), 7.30–7.26 (m, 1H), 6.54 (dd, $J = 9.8, 5.2$ Hz, 1H), 5.96 (ddd, $J = 17.4, 10.7, 5.5$ Hz, 1H), 5.83–5.55 (m, 1H), 5.42 (d, $J = 10.7$ Hz, 1H), 5.32 (d, $J = 17.4$ Hz, 1H), 4.01–3.88 (m, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 161.2, 148.4, 146.6, 132.6, 131.3, 131.1, 121.3, 121.0, 120.9, 120.8, 120.2, 62.9, 59.1; HRMS (ESI-MS): Calcd. for $C_9H_{10}FNO_2$ (M+H): 184.0774, Found: 184.0771; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/6, t_{major} = 5.76 min, t_{minor} = 8.44 min; 93.5:6.5 *er*.

(S)- 5-fluoro-1-(1-hydroxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 85%; colorless oil; $[\alpha]_D^{25} = -80.29$ ($c = 0.20$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.37 (d, $J = 7.4$ Hz, 1H), 6.58 (s, 1H), 6.27 (dd, $J = 7.4, 2.4$ Hz, 1H), 5.96 (ddd, $J = 16.5, 10.6, 5.5$ Hz, 1H), 5.53–5.49 (m, 1H), 5.41 (d, $J = 10.7$ Hz, 1H), 5.30 (d, $J = 17.4$ Hz, 1H), 3.99–3.89 (m, 2H), 3.73 (bs, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 162.2, 146.8, 136.1, 132.7, 120.0, 118.8, 108.2, 62.8, 58.9; HRMS (ESI-MS): Calcd. for $C_9H_{10}ClNO_2$ (M+H): 200.0478, Found: 200.0478; HPLC conditions: Chiralcel AD-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/3, t_{minor} = 4.85 min, t_{major} = 6.76 min; 92.5:7.5 *er*.

(S)- 5-bromo-1-(1-hydroxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 87%; light yellow solid; 76–79 °C; $[\alpha]_D^{25} = -45.06$ ($c = 0.68$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.55 (d, $J = 2.7$ Hz, 1H), 7.35 (dd, $J = 9.6, 2.6$ Hz, 1H), 6.46 (d, $J = 9.6$ Hz, 1H), 5.97 (ddd, $J = 16.2, 10.7, 5.6$ Hz, 1H), 5.54–5.50 (m, 1H), 5.42 (d, $J = 10.6$ Hz, 1H), 5.33 (d, $J = 17.4$ Hz, 1H), 4.16–4.09 (m, 1H), 3.98–3.89 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 161.4, 142.4, 135.8, 132.6, 121.4, 120.2, 98.4, 62.6, 59.2; HRMS (ESI-MS): Calcd. for $C_9H_{10}BrNO_2$ (M+H): 243.9973, Found: 243.9977; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/3, t_{major} = 12.66 min, t_{minor} = 14.56 min; 94:6 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-5-iodopyridin-2(1H)-one




Yield: 85%; yellow solid; 70-72 °C; $[\alpha]_D^{25} = -120.19$ ($c = 2.32$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.60 (d, $J = 2.4$ Hz, 1H), 7.44 (dd, $J = 9.5, 2.5$ Hz, 1H), 6.37 (d, $J = 9.5$ Hz, 1H), 5.96 (ddd, $J = 16.2, 10.6, 5.6$ Hz, 1H), 5.51–5.47 (m, 1H), 5.42 (d, $J = 10.7$ Hz, 1H), 5.32 (d, $J = 17.4$ Hz, 1H), 4.15 (dd, $J = 5.8, 5.8$ Hz, 1H), 3.98–3.87 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 161.5, 146.9, 140.7, 132.7, 122.0, 120.2, 65.0, 62.6, 59.2; HRMS (ESI-MS): Calcd. for $\text{C}_9\text{H}_{10}\text{INO}_2$ ($\text{M}+\text{H}$): 291.9834, Found: 291.9833; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 2/8, $t_{\text{major}} = 18.57$ min, $t_{\text{minor}} = 21.82$ min; 94:6 *er*.

(S)- 3,5-dibromo-1-(1-hydroxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 88%; brown solid; 110-112 °C; $[\alpha]_D^{25} = -118.46$ ($c = 2.20$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.80 (d, $J = 2.5$ Hz, 1H), 7.58 (d, $J = 2.6$ Hz, 1H), 5.97 (ddd, $J = 16.6, 10.6, 5.8$ Hz, 1H), 5.58–5.54 (m, 1H), 5.44 (d, $J = 10.6$ Hz, 1H), 5.37 (d, $J = 17.4$ Hz, 1H), 4.03–3.92 (m, 2H), 3.72 (dd, $J = 6.2, 6.0$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.0, 143.8, 135.3, 132.2, 120.8, 116.8, 97.3, 62.5, 60.8; HRMS (ESI-MS): Calcd. for $\text{C}_9\text{H}_9\text{Br}_2\text{NO}_2$ ($\text{M}+\text{H}$): 321.9078, Found: 321.9077; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 1/6, $t_{\text{major}} = 52.21$ min, $t_{\text{minor}} = 57.60$ min; 96:4 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-5-(trifluoromethyl)pyridin-2(1H)-one




Yield: 85%; light yellow oil; $[\alpha]_D^{25} = -12.70$ ($c = 0.56$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.82 (s, 1H), 7.46 (dd, $J = 9.6, 2.6$ Hz, 1H), 6.61 (d, $J = 9.6$ Hz, 1H), 5.99 (ddd, $J = 16.6, 10.7, 5.6$ Hz, 1H), 5.59–5.55 (m, 1H), 5.47 (d, $J = 10.6$ Hz, 1H), 5.37 (d, $J = 17.4$ Hz, 1H), 4.02–3.94 (m, 2H), 3.46 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 162.4, 135.6, 135.5, 135.10, 135.0, 132.2, 126.5, 124.3, 122.2, 120.9, 120.8, 110.4, 110.1, 109.8, 109.6, 62.6, 62.6, 59.2; HRMS (ESI-MS): Calcd. for $\text{C}_{10}\text{H}_{10}\text{F}_3\text{NO}_2$ ($\text{M}+\text{H}$): 234.0742, Found: 234.0743; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 2/8, $t_{\text{major}} = 8.28$, $t_{\text{minor}} = 9.90$ min; 94:6 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile




Yield: 82%; light yellow oil; $[\alpha]_D^{25} = -10.29$ ($c = 0.52$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 7.84 (dd, $J = 7.2, 2.0$ Hz, 1H), 7.78 (dd, $J = 6.9, 2.0$ Hz, 1H), 6.38 (dd, $J = 7.0, 7.0$ Hz, 1H), 5.99 (ddd, $J = 16.6, 10.6, 5.8$ Hz, 1H), 5.61–5.57 (m, 1H), 5.45 (d, $J = 10.6$ Hz, 1H), 5.36 (d, $J = 17.4$ Hz, 1H), 4.04–3.96 (m, 2H), 3.52 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 160.3, 147.0, 141.8, 132.0, 120.9, 115.7, 105.8, 104.7, 62.3, 59.9; HRMS (ESI-MS): Calcd. for $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_2$ ($\text{M}+\text{Na}$): 213.0640, Found: 213.0637; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 3/7, $t_{\text{minor}} = 10.32$ min, $t_{\text{major}} = 13.92$ min; 90:10 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-5-nitropyridin-2(1H)-one




Yield: 86%; brown solid; 109–111 °C; $[\alpha]_D^{25} = -4.33$ ($c = 0.84$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 8.75 (d, $J = 3.2$ Hz, 1H), 8.10 (dd, $J = 10.0, 3.0$ Hz, 1H), 6.56 (d, $J = 10.0$ Hz, 1H), 6.04 (ddd, $J = 16.7, 10.6, 5.9$ Hz, 1H), 5.60–5.57 (m, 1H), 5.54 (d, $J = 10.6$ Hz, 1H), 5.45 (d, $J = 17.4$ Hz, 1H), 4.06–4.00 (m, 2H), 2.99 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 161.8, 138.2, 133.1, 131.6, 130.9, 121.7, 119.0, 62.4, 59.5; HRMS (ESI-MS): Calcd. for $\text{C}_9\text{H}_{10}\text{N}_2\text{O}_4$ ($\text{M}+\text{H}$): 211.0719, Found: 211.0718; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 2/8, $t_{\text{major}} = 7.23$ min, $t_{\text{minor}} = 8.06$ min; 93:7 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)-6-oxo-1,6-dihydropyridine-3-carbaldehyde



Yield: 88%; light yellow solid; 90–92 °C; $[\alpha]_D^{25} = -32.49$ ($c = 1.20$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 9.60 (s, 1H), 8.09 (d, $J = 2.4$ Hz, 1H), 7.80 (dd, $J = 9.5, 2.4$ Hz, 1H), 6.58 (d, $J = 9.4$ Hz, 1H), 6.04 (ddd, $J = 16.4, 10.6, 5.6$ Hz, 1H), 5.62–5.58 (m, 1H), 5.50 (d, $J = 10.6$ Hz, 1H), 5.40 (d, $J = 17.6$ Hz, 1H), 4.05 (dd, $J = 12.0, 4.9$ Hz, 1H), 4.05 (dd, $J = 8.5, 4.9$ Hz, 1H), 3.33 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 186.5, 162.9, 145.6, 135.6, 132.2, 121.0, 120.5, 118.3, 62.5, 59.0; HRMS (ESI-MS): Calcd. for $\text{C}_{10}\text{H}_{11}\text{NO}_3$ ($\text{M}+\text{H}$): 194.0817, Found: 194.0816; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, i -PrOH/hexanes = 1/2, $t_{\text{major}} = 30.13$ min, $t_{\text{minor}} = 33.28$ min; 91.5:8.5 *er*.


methyl (S)-1-(1-hydroxybut-3-en-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxylate



Yield: 83%; white solid; 85–87 °C; $[\alpha]_D^{25} = -33.96$ ($c = 1.28$, CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ 8.15–8.13 (m, 1H), 7.70 (dd, $J = 6.8, 2.2$ Hz, 1H), 6.30 (dd, $J = 6.9, 7.0$ Hz, 1H), 6.00 (ddd, $J = 16.5, 10.7, 5.6$ Hz, 1H), 5.70 (q, $J = 6.4$ Hz, 1H), 5.40 (d, $J = 10.6$ Hz, 1H), 5.33 (d, $J = 17.4$ Hz, 1H), 4.04–3.93 (m, 2H), 3.86 (s, 3H), 3.82 (bs, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 165.5, 159.8, 144.7, 141.2,


133.0, 120.0, 119.8, 104.9, 62.6, 59.2, 52.2; HRMS (ESI-MS): Calcd. for $C_{11}H_{13}NO_4$ (M+Na): 246.0742, Found: 246.0741; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 3/7, $t_{\text{minor}} = 7.90$ min, $t_{\text{major}} = 10.80$ min; 90:10 *er*.

(R)-1-(5-hydroxypent-1-en-3-yl)pyridin-2(1H)-one




Yield: 76%; light yellow liquid; $[\alpha]_D^{25} = -14.09$ ($c = 0.36$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.38 (ddd, $J = 11.0, 8.2, 2.6$ Hz, 1H), 7.27 (dd, $J = 8.8, 2.5$ Hz, 1H), 6.63 (d, $J = 11.4$ Hz, 1H), 6.30 (dd, $J = 8.4, 8.4$ Hz, 1H), 6.00 (ddd, $J = 19.4, 13.4, 6.0$ Hz, 1H), 5.83–5.77 (m, 1H), 5.42 (d, $J = 5.3$ Hz, 1H), 5.39 (d, $J = 14.1$ Hz, 1H), 4.10 (dd, $J = 12.4, 5.2$ Hz, 1H), 3.68–3.60 (m, 1H), 3.30–3.23 (m, 1H), 2.32–2.23 (m, 1H), 1.74–1.66 (m, 1H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 163.4, 139.5, 136.3, 134.2, 120.2, 118.6, 107.4, 57.4, 52.4, 35.8; HRMS (ESI-MS): Calcd. for $C_{10}H_{13}NO_2$ (M+H): 180.1025, Found: 180.1024; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 2/8, $t_{\text{major}} = 11.83$ min, $t_{\text{minor}} = 16.57$ min; 95:5 *er*.

(S)-1-(1-methoxybut-3-en-2-yl)pyridin-2(1H)-one




Yield: 39%; colorless oil; $[\alpha]_D^{25} = -12.56$ ($c = 0.28$, CH_2Cl_2); 1H NMR (500 MHz, $CDCl_3$) δ 7.42 (dd, $J = 7.0, 2.0$ Hz, 1H), 7.31 (ddd, $J = 8.9, 6.5, 2.0$ Hz, 1H), 6.58 (d, $J = 9.2$ Hz, 1H), 6.17 (dd, $J = 6.7, 6.8$ Hz, 1H), 6.00 (ddd, $J = 16.2, 10.6, 5.4$ Hz, 1H), 5.79–5.75 (m, 1H), 5.37 (d, $J = 10.7$ Hz, 1H), 5.27 (d, $J = 17.4$ Hz, 1H), 3.79 (dd, $J = 10.4, 5.4$ Hz, 1H), 3.69 (dd, $J = 10.4, 4.2$ Hz, 1H), 3.34 (s, 3H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 162.3, 139.0, 135.8, 133.5, 120.4, 119.1, 105.6, 72.7, 59.0, 55.6; HRMS (ESI-MS): Calcd. for $C_{10}H_{13}NO_2$ (M+H): 180.1025, Found: 180.1021; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 1/9, $t_{\text{major}} = 20.67$ min, $t_{\text{minor}} = 23.11$ min; 64:36 *er*.

(S)-1-(1-hydroxybut-3-en-2-yl)pyridin-4(1H)-one




Yield: 40%; white solid; 64–66 °C; $[\alpha]_D^{25} = -17.36$ ($c = 0.52$, CH_2Cl_2); 1H NMR (500 MHz, CD_3OD) δ 7.88 (d, $J = 7.6$ Hz, 2H), 6.48 (d, $J = 7.6$ Hz, 2H), 6.08 (ddd, $J = 17.0, 10.7, 6.0$ Hz, 1H), 5.44 (d, $J = 10.6$ Hz, 1H), 5.32 (d, $J = 17.3$ Hz, 1H), 4.72–4.68 (m, 1H), 3.95–3.88 (m, 2H); ^{13}C NMR (125 MHz, CD_3OD) δ 181.6, 142.9, 134.4, 121.3, 118.8, 71.9, 64.4; HRMS (ESI-MS): Calcd. for $C_9H_{11}NO_2$ (M+H): 166.0868, Found: 166.0866; HPLC conditions: Chiralcel AS-H column, 220 nm, flow rate: 1.0 mL/min, *i*-PrOH/hexanes = 3/7, $t_{\text{minor}} = 27.90$ min, $t_{\text{major}} = 34.44$ min; 83.5:16.5 *er*.

General procedure for ring-closing metathesis of **3a** and **4a** to **9a** and **9b**




(*S*)-1-(1-(allyloxy)but-3-en-2-yl)pyridin-2(1*H*)-one




To the solution of **3a** in THF (50.0 mg, 0.303 mmol), *t*BuOK (68.0 mg, 0.606 mmol) was added at 0°C and the solution was stirred at room temperature for 30 minutes. Then allyl bromide (29 μ L, 0.333 mmol) was added dropwise and the solution was further stirred at room temperature for 2 hours. After filtration, the mixture was extracted with CH₂Cl₂, dried over anhydrous Na₂SO₄, and the solvent was removed in vacuum. The crude product was purified by flash column chromatography on silica gel to afford **8a** as colorless oil in 96% yield (59.8 mg). ¹H NMR (500 MHz, CDCl₃) δ 7.45 (dd, *J* = 6.9, 2.0 Hz, 1H), 7.31 (ddd, *J* = 9.4, 6.6, 2.2 Hz, 1H), 6.58 (d, *J* = 9.2 Hz, 1H), 6.17 (dd, *J* = 6.8, 1.5 Hz, 1H), 6.03 (ddd, *J* = 16.2, 10.7, 5.5 Hz, 1H), 5.82 (ddd, *J* = 16.0, 10.7, 5.6 Hz, 1H), 5.78–5.75 (m, 1H), 5.37 (d, *J* = 10.6 Hz, 1H), 5.29 (d, *J* = 17.4 Hz, 1H), 5.24–5.14 (m, 2H), 4.00–3.93 (m, 2H), 3.84 (dd, *J* = 10.4, 5.2 Hz, 1H), 3.75 (dd, *J* = 10.4, 4.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 162.4, 139.1, 136.0, 134.0, 133.6, 120.4, 119.3, 117.2, 105.6, 72.0, 70.0, 55.9; HRMS (ESI-MS): Calcd. for C₁₂H₁₅NO₂ (*M*+*H*): 206.1121, Found: 206.1121.

(*R*)-1-(5-(allyloxy)pent-1-en-3-yl)pyridin-2(1*H*)-one



Yield: 87%; colorless oil; ¹H NMR (500 MHz, CDCl₃) δ 7.31–7.27 (m, 1H), 7.24 (d, *J* = 7.0 Hz, 1H), 6.56 (d, *J* = 9.2 Hz, 1H), 6.19 (dd, *J* = 6.7, 6.7 Hz, 1H), 6.01 (ddd, *J* = 17.2, 10.4, 5.6 Hz, 1H), 5.89–5.80 (m, 1H), 5.66–5.62 (m, 1H), 5.28 (d, *J* = 10.5 Hz, 1H), 5.22 (d, *J* = 17.2 Hz, 1H), 5.21 (d, *J* = 17.2 Hz, 1H), 5.13 (d, *J* = 10.4 Hz, 1H), 3.94–3.86 (m, 2H), 3.46–3.38 (m, 2H), 2.23–2.06 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 162.3, 138.7, 136.4, 134.6, 134.4, 120.7, 117.6, 116.8, 106.0, 71.8, 66.5, 54.6, 33.0; HRMS (ESI-MS): Calcd. for C₁₃H₁₇NO₂ (*M*+*H*): 220.1338, Found: 220.1334.


(*S*)-1-(3,6-dihydro-2*H*-pyran-3-yl)pyridin-2(1*H*)-one



9a

According to the reported procedure,⁴ under nitrogen atmosphere compound **8a** (46.0 mg, 0.224 mmol), Grubbs 1st generation catalyst (9.23 mg, 0.011 mmol, 5 mol%), and anhydrous degassed CH_2Cl_2 (2.0 mL) were added into a Schlenk flask in order and the mixture was refluxed at 40 °C for overnight. After cooling to room temperature, the reaction mixture was concentrated under reduce pressure and the resulting residue was chromatographed on silica gel (EA/PE = 2/8 to give the desired product **9a** as colorless oil (37.3 mg, 94%). ^1H NMR (500 MHz, CDCl_3) δ 7.64–7.62 (m, 1H), 7.35–7.31 (m, 1H), 6.58 (d, J = 9.2 Hz, 1H), 6.30 (d, J = 10.2 Hz, 1H), 6.19 (dd, J = 6.8, 6.7 Hz, 1H), 5.87–5.84 (m, 1H), 5.50–5.47 (m, 1H), 4.33–4.28 (m, 1H), 4.19 (dd, J = 17.0, 2.4 Hz, 1H), 3.97–3.91 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 162.4, 139.4, 135.6, 133.3, 122.4, 120.0, 105.7, 68.9, 65.2, 47.7; HRMS (ESI-MS): Calcd. for $\text{C}_{10}\text{H}_{11}\text{NO}_2$ (M+H): 178.0868, Found: 178.0866.

(R)-1-(2,3,4,7-tetrahydrooxepin-4-yl)pyridin-2(1H)-one







9b


Yield: 89%; colorless oil; ^1H NMR (500 MHz, CDCl_3) δ 7.53 (dd, J = 6.9, 1.8 Hz, 1H), 7.34–7.30 (m, 1H), 6.57 (d, J = 9.1 Hz, 1H), 6.21 (dd, J = 6.8, 6.6 Hz, 1H), 6.03–5.99 (m, 1H), 5.91–5.88 (m, 1H), 5.66 (d, J = 11.6 Hz, 1H), 4.35–4.22 (m, 2H), 3.88–3.75 (m, 2H), 2.26–2.16 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 162.0, 139.2, 135.4, 134.0, 130.7, 120.5, 106.0, 67.3, 67.0, 54.6, 34.8; HRMS (ESI-MS): Calcd. for $\text{C}_{11}\text{H}_{13}\text{NO}_2$ (M+H): 192.1025, Found: 192.1024.



References:



- (1) M. Guangning, A. Samson, D. Luca, P. Carlos, L. Leifeng, S. Junliang, I. Ismail and C. Armando, *Angew. Chem., Int. Ed.*, 2013, **52**, 6054.
- (2) I. K. Kavrakova and M. J. Lyapova, *Collect. Czech. Chem. Commun.*, 2000, **65**, 1586.
- (3) R. Alessandro, E. L. Ernest and A. B. Robert, *Org. Lett.*, 2010, **12**, 2637.
- (4) B. M. Trost, B. S. Brown, E.-J. McEachern and O. Kuhn, *Chem. - Eur. J.*, 2003, **9**, 4451.








































































3m




























8a








8b





9a





9b

